8-K: Odyssey Therapeutics Completes Private Placement Alongside IPO

Odyssey Therapeutics, Inc. announced the closing of a private placement of 1,388,889 shares of common stock at $18.00 per share, concurrent with its initial public offering.

Summary

• Odyssey Therapeutics, Inc. entered into a Share Purchase Agreement on May 7, 2026, with TPG LSI Rise Orazio II, L.P., an affiliate of an existing stockholder.
• The agreement involved the purchase of 1,388,889 shares of the Company's common stock at $18.00 per share.
• This private placement financing closed concurrently with the Company's initial public offering (IPO).
• The shares were sold under Section 4(a)(2) of the Securities Act, with the purchaser represented as an institutional accredited investor or qualified institutional buyer.
• The Company also filed an amended and restated certificate of incorporation and amended and restated bylaws, effective May 11, 2026, in connection with the IPO closing.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, indicating successful capital raising through a private placement alongside the IPO, demonstrating investor confidence and completion of key corporate actions.

Positives

• Successful concurrent private placement alongside IPO, indicating strong investor interest.
• Raised capital through the private placement at the IPO price of $18.00 per share.
• Secured a significant purchase of 1,388,889 shares by an affiliate of an existing stockholder, demonstrating continued support.
• Amended and restated corporate documents (certificate of incorporation and bylaws) to align with public company status.

Negatives

• A placement agent fee of 7.0% of the total purchase price was paid, reducing net proceeds from the private placement.

Risks

• The shares purchased in the private placement were not registered under the Securities Act, relying on exemptions which may have specific compliance requirements.
• The Purchase Agreement contains customary representations and warranties that could lead to future claims if breached.
• The registration rights granted under the Investor Rights Agreement are subject to specified holder thresholds and other conditions, which could impact future liquidity for these shares.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the completion of the private placement and IPO, and the amendments to corporate documents.

Industry Context

StockSavvy.ai notes that concurrent private placements alongside IPOs are a common strategy for biotechnology companies to secure additional capital from strategic investors or existing stakeholders, often to bolster the balance sheet before or immediately after becoming a public entity.

Corporate Governance

Related Party Transactions

• The private placement involved TPG LSI Rise Orazio II, L.P., identified as an affiliate of an existing stockholder, purchasing shares.

Stakeholder Impact

• Shareholders: The private placement at the IPO price dilutes existing shareholders but also provides capital for company operations and growth.
• Investors in the private placement: Gain ownership in a public company with registration rights, subject to certain conditions.
• Placement Agents: Received a 7.0% fee on the total purchase price of the private placement shares.

Next Steps

• The shares purchased in the private placement are subject to registration rights under the Third Amended and Restated Investor Rights Agreement.
• The company has updated its corporate charter and bylaws to reflect its status as a public entity.

Key Dates

Recommendation

The filing details a private placement concurrent with an IPO, which is a standard event. While it confirms capital raising and corporate structure updates, it doesn't provide new operational or clinical data that would strongly influence a buy or sell decision. It's a confirmation of expected events.

Keywords

Odyssey Therapeutics, 8-K, Private Placement, IPO, Share Purchase Agreement, Common Stock, SEC Filing, TPG LSI Rise Orazio II